Esperion Partner Otsuka Receives Approval for Nexletol in Japan
MT Newswires Live
Sep 19
Esperion (ESPR) said Friday its partner, Otsuka Pharmaceutical, has received approval from the Japanese Ministry of Health to market Nexletol for treating high cholesterol and familial high cholesterol.
After the approval, Nexletol is now available in the US, Europe and Japan to treat hypercholesterolemia, the company said.
As part of the collaboration agreement, Esperion is eligible for milestone payments and royalties based on Otsuka's sales in Japan.
Shares of the company were up 4% in recent Friday premarket activity.
Price: 2.87, Change: +0.12, Percent Change: +4.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.